Fujifilm Diosynth celebrates expansion in Denmark

By The Science Advisory Board staff writers

March 4, 2021 -- Contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies held a ceremony on March 3 to celebrate the large-scale expansion of cell culture capacity at its production facility in Hillerød, Denmark.

The expansion project includes the addition of six 20,000-L bioreactors, which represents a doubling of the facility's bulk drug substance production capacity and the installation of fill/finish capability to support production of approximately 35 million units per year, Fujifilm Diosynth said in a statement.

Turning of the soil at Fujifilm Diosynth Biotechnologies in Denmark signals the start of expansion project. Image courtesy of Fujiflim Diosynth.

The revamp was made possible by a capital investment of 100 billion yen ($928 million U.S.) from parent company Fujifilm. Fujifilm Diosynth said that it is adding 300 staff in Denmark by the end of 2023 to support new activities.

Copyright © 2021 scienceboard.net
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here